The overall prognosis of stage I borderline ovarian tumors (BOT) is excellent but a small percentage of patients die to their disease. The prognostic factors for such a rare event are still not clearly defined. The aim of this study was to determine these factors for recurrence per se and recurrence in the form of invasive carcinoma in a large series of stage I tumors. The risks of recurrences were statistically increased after conservative treatment, particularly after a cystectomy, in patients with stage IB and among patients with incompletely staged tumors. In the subgroup of conservatively treated patients (representing 75% of our population), the risks of recurrences were statistically increased in patients affected by a SBOT, in patients who had undergone a cystectomy, in patients with stage IB disease and in patients with a micropapillary pattern (MPP). MBOT and the presence of a MPP were identified as prognostic factors for invasive disease.
introduction
In patients with borderline ovarian tumors (BOT) confined to the ovary(ies) (stage I disease), the risk of progression to an invasive carcinoma (and subsequent death) is very low (<1%-3%) [1, 2] . However, as such events are really rare, to date no 'highrisk' group has been clearly identified for such potentially lethal progression in early-stage disease [3, 4] . Some series suggested that the tumor histological subtypes [ particularly in mucinous BOT (MBOT)] have an impact on a higher risk of recurrent invasive disease but this point continues to fuel debate in the literature [5] [6] [7] .
The focus of the present series is to analyze the prognostic factors for recurrence and progression to invasive carcinoma, in a large series of stage I disease, comprising the largest number of conservatively treated patients reported to date. This analysis will also be focused on the impact of the histological subtype [serous BOT (SBOT) or MBOT] on these risks of recurrence and of progression to carcinoma.
patients
From July 2000 to November 2010, 254 patients treated at or referred to Gustave Roussy and Hopital Tenon after surgical treatment alone of a stage I SBOT and with follow-up data were analyzed. Study inclusion criteria were as follows: a centralized histopathological review of the primary ovarian tumor (and of recurrent disease, in case of a relapse) by the reference expert pathologist (PD and AC) with similar and homogeneous pathological criteria; pure serous or mucinous BOT subtype; macroscopic (and/or microscopic if staging surgery had been complete) stage I disease. MBOT with peritoneal pseudomyxoma and/or a morphological appearance of metastatic disease from a primary extraovarian tumor were excluded.
BOT was defined and classified according to WHO criteria [8] . The micropapillary pattern (MPP) of the serous ovarian tumor was defined according to criteria established by Burks RE, Sherman ME, Seidman JD and Kurman RJ [9] . MBOT could be classified as intestinal or endocervical-like (or 'mullerian') subtypes [8] . In some cases of MBOT, architectural and cytological features of adenocarcinoma (with marked nuclear atypia) can be observed but without stromal invasion [defining 'intraepithelial carcinoma' (IEC)].
In both subtypes, stromal microinvasion (SMI) can be observed on the ovarian tumor and was defined as the presence of stromal invasion <10 mm 2 [8] . The 1987 FIGO classification was used for staging. The stage described during the surgical procedure and that found in the pathology reports was recorded. All patients included in the present series had macroscopic (and microscopic if peritoneal staging surgery had been carried out) stage I disease. If a peritoneal recurrence had occurred, the type of peritoneal implants at relapse was classified as noninvasive or invasive according to the absence or presence of stromal invasion of the peritoneum, respectively [8] .
treatments Surgery was defined as radical [bilateral salpingo-oophorectomy (BSO) with or without a hysterectomy] or conservative, in order to preserve subsequent fertility. Conservative treatment was defined as uterus-conserving surgery with salvaging of at least a portion of one ovary. Thus, four types of conservative surgical procedures could have been carried out: unilateral adnexectomy (UA), UA + contralateral cystectomy, unilateral cystectomy and bilateral cystectomy. Additional surgical procedures had occasionally been carried out: peritoneal cytology, biopsies of the contralateral ovary (during conservative treatment), an omentectomy, multiple peritoneal biopsies and an appendectomy, particularly in MBOT. Peritoneal surgical staging was considered complete in the present paper if it included at least peritoneal cytology, an omentectomy or an omental biopsy, peritoneal biopsies and an appendectomy (in MBOT) carried out during a one-or two-step (at the time of restaging surgery) procedure.
follow-up and recurrence
Patient follow-up had included a clinical examination, blood tests (CA 125 and/or CA 19.9 levels according to the subtype), and an ultrasound scan in case of conservative treatment, every 3 months during the first year following the procedure, then every 6 months for 2 years and then yearly thereafter.
A recurrence could have been 'borderline' or noninvasive (in case of a purely borderline recurrence and/or noninvasive peritoneal implants) or 'invasive', if the (ovarian or extraovarian) recurrent disease exhibited clear-cut histological features of adenocarcinoma.
statistical analysis
The principal end point for this analysis was the 5-year invasive relapse-free interval. Overall recurrence rate and recurrence rate under the form of invasive disease were determined in the entire population and specifically according to the histologic subtype of the BOT (MBOT or SBOT). The invasive relapse free interval was defined as the time from the surgery to invasive relapse, the relapse-free interval was defined as the time from the surgery to relapse (borderline or invasive). Patients who had not experienced an event at the time of analysis were censored at the date of last follow-up. Patients deceased without event were censored at the time of death.
Prognostic factors of recurrence and specifically invasive recurrence were analyzed. These factors were also studied specifically in the subgroup of patients treated conservatively (which represent 75% of our population) having traditionally a higher risk of recurrence. Impact of micropapillary disease and intraepithelial carcinoma were specifically determined respectively in SBOT and MBOT subgroup.
All curves were calculated using the Kaplan-Meier method. The 95% confidence interval was calculated using the Rothman procedure. The log-rank test was used to compare the curves and to determine the P value. The χ 2 test was used for descriptive analysis. Medians were compared using the Kruskall-Wallis test. A P value <0.05 was considered significant. All calculations were carried out with SAS software version 9.3 (SAS Institute, Inc., Cary, NC).
results
Among the 254 patients fulfilling inclusion criteria, 140 had MBOT and 114 SBOT. One-hundred ninety-one patients (75%) had undergone conservative treatment (100 MBOT and 91 SBOT) and 63, radical treatment after a 1-step (N = 201) or a 2-step (N = 43) procedure. Patient clinical, surgical and histological characteristics according to the histological subtype are given in Table 1 and supplementary Table S1 , available at Annals of Oncology online.
recurrence, survival and progression to malignant carcinoma In cases of SBOT, six had synchronous noninvasive peritoneal implants. In MBOT, seven had homolateral ovarian recurrences and one a contralateral recurrence (all of them without peritoneal spread).
The median interval to the onset of invasive recurrences was respectively 32 (7-48) and 29 (14-75) months (NS) in SBOT and MBOT. The characteristics of the 12 patients who had developed an invasive recurrence are given in supplementary Table S2 , available at Annals of Oncology online. Three patients had died of disease among cases with MBOT and one among cases with SBOT.
prognostic factors for recurrence (whatever the histological subtype of recurrent disease)
Prognostic factors for all recurrent lesions and recurrences in the form of invasive disease are detailed in Table 2 . The risks of recurrence (borderline and invasive) were statistically increased after conservative treatment, in SBOT, in patients with stage IB disease and in patients in whom staging was incomplete (Table 2) . Only the disease stage had a significant impact on the risk of an invasive recurrence.
The prognostic factors for recurrence and an invasive recurrence in patients treated conservatively (who represented 75% of our population) are specifically detailed in Table 3 . The risks of The times to relapse according to the histological subtypes are given in Figure 1 . Six patients had died in the present series: four as a result of disease and two due to intercurrent disease. Figure 2 shows the cumulative risk of progression to an invasive recurrence in 191 conservatively treated patients.
discussion
The results of the present series raise several questions and could have an impact on the future management of BOT. The retrospective nature of our study could be criticized, but as BOT are relatively rare, all the 'large' series published on this disease were retrospective studies [4, 7, [10] [11] [12] [13] [14] [15] . This theoretical 'weakness' (observed in all series about BOT) is offset by the centralized pathological review which is a crucial step in homogenizing the interpretability of different important histological characteristics (IEC, SMI, MPP, etc.). But, as a majority of cases reported here are patients treated initially outside from our institutions but referred for pathological review and advice, sampling was initially done by the first pathologists who see the specimen. Selected paraffin-embedded blocks were then sent to our institutions for pathological review. Most of the patients with MBOT had a large-sized tumor (particularly among the intestinal subtype). In such patients with bulky disease, the risk is that initial sampling (or blocks finally sent for pathological review) missed the region with potentially invasive carcinoma. To decrease this risk, recommendations have been done since one decade to carry out one section per centimeter in tumor <10 cm and two sections per centimeter for larger tumors excluding smooth-walled cstic foci) [16, 17] . Such recommendations have been applied during this study period.
We focus our study 'exclusively' on patients with stage I disease (exclusion of autoimplants or extraovarian implants) and with 'pure' histological subtypes (exclusion of mixed subtypes) to really measure the prognostic impact of histologic subtype in early-stage disease. In fact, peritoneal spread is more frequent in SBOT (15%-40%) whereas this is exceptional is MBOT. Thus, when we compare the outcomes of SBOT and MBOT, without taking into account the difference in terms of the disease stage between the two groups, the rate of recurrence is similar or not statistically different. But the main question in early-stage BOT is to evaluate the outcome between the two subtypes in stage I disease, focusing particularly on the risk of an invasive recurrence, the only factor likely to have an impact on overall survival [2, 6] .
In the present series, we were unable to study the prognostic factors for overall survival because, fortunately (like in the few other large series of stage I BOT), disease-related deaths were rare (four in the present series) [7, 10, [17] [18] [19] [20] . However, the rate of invasive recurrences is of interest because, in such cases, even if the patients were alive at the time of the publication, further survival could be impaired by a new relapse. We therefore analyzed two main end points in the present series: the overall rate of recurrences (borderline or invasive) and more originally (and with a more fascinating clinical impact) the specific rate of invasive recurrences.
One of the particular characteristics of our population is the high rate of conservative treatment (representing 75% in our study). This could be easily explained by the fact that both teams involved in the present series have been working for two decades on this topic and have a specific recruitment in this situation [3] . We have known, for a long time, that conservative management increases the recurrence rate compared with radical management (BSO) [3] . However, questions are now emerging about the risk of invasive recurrences (and therefore of the potential impact on survival) after fertility-sparing surgery in BOT [3] . The further implications are then crucial because they could question the validity and the safety of this management in a selected 'high-risk' group [2] . This is why we also focused the analysis on the prognostic factors for (invasive) recurrences in the subgroup of conservatively treated patients. It is noteworthy that the number of patients treated in the present series with fertility-sparing surgery (191 cases) is the largest reported in the literature to date (with a complete study of prognostic factors) [4, 7, 10, 11, 14, 15] (Table 4) .
If we focus on the risk factors for overall recurrences (borderline and invasive) for all patients, we find that the use of conservative treatment (and particularly cystectomy) and incompletely staged disease increased the rate of relapse. Nevertheless, those factors did not exert a statistical impact on the invasive recurrence rate because most of the recurrences were borderline tumors, unlikely to have a further impact on patient outcomes. These two points explain why fertility-sparing surgery remains the 'standard treatment' in young patients with early-stage I BOT and also why the impact on overall survival of complete staging surgery in BOT remains unproven and therefore its interest is still debated [3, 12] .
When we focus on the large subgroup of patients treated conservatively, the impact of the histological subtype is substantial. It is noteworthy that patients with MBOT relapsed less frequently than those with SBOT, but when a relapse occurred, the risk of an invasive recurrence was significantly higher for MBOT (8 of 15 recurrences in MBOT occurred in the form of carcinoma compared with 1 of 24 in SBOT). These results are very interesting because finally, this study shows that the tumor histological subtype is the 'only' factor capable of defining a 'high-risk' group of BOT. Another factor attained statistical significance for an invasive recurrence, i.e. the presence of a MPP. However, even if the P value is 0.01 for this factor, we only have one event, so this result is of more limited value compared with the previous one.
Our results do not condemn fertility-sparing surgery in MBOT but they suggest that the mucinous subgroup of BOT belong to a small 'high-risk' group likely to develop an invasive recurrence after such surgery. Moreover, they raise the question of completion surgery (removal of the remaining ovary) after childbirth and/or in patients beyond the child-bearing age.
Finally, our results show that MBOT carry a worse prognosis compared with SBOT but we lack clear evidence as to whether this is due to the particular natural history of this tumor or to the fact that, as MBOT are bulky tumors (especially the intestinal subtype), a small part of a 'true' invasive carcinoma may 
